Major Milestones: Certara Celebrates Research Advances in 2024

Certara Celebrates Remarkable Research Achievements in 2024

Certara, Inc. (NASDAQ: CERT), a prominent leader in model-informed drug development, is excited to showcase its significant contributions to the research community with over 100 publications in 2024. This milestone not only underscores Certara's commitment to scientific excellence but also highlights the dedication of its talented researchers to advance the understanding and development of new therapeutics.

Recognition Among Top Scientists

This year, 12 scientists from Certara were honored in the prestigious Stanford/Elsevier list recognizing the top one percent of the most-cited researchers worldwide. This list, now in its seventh edition, encompasses a wide array of scientific disciplines and sub-disciplines, showcasing the impact that Certara's scientists have made through their research.

Outstanding Researchers at Certara

Among the distinguished researchers included in the evaluation are:

• Amin Rostami-Hodjegan, Chief Scientific Officer at Simcyp
• Frederic Bois, Senior Scientific Advisor & Head of Mechanistic Modelling
• Hannah Jones, Senior Vice President, Head of Simcyp PBPK Modelling Services
• Hugo Geerts, Head of QSP Neurosciences
• Khaled Abduljalil, Senior Principal Scientist at Simcyp
• Karen Rowland-Yeo, Senior Vice President, Client & Regulatory Strategy
• Masoud Jamei, Senior Vice President of Research and Development at Simcyp
• Piet H van der Graaf, Senior Vice President and Head of Quantitative Systems Pharmacology
• Patrick Smith, President of Certara Drug Development Solutions
• Rajesh Krishna, Distinguished Scientist, Drug Development Science
• Stephen Duffull, Senior Scientific Advisor
• Trevor Johnson, Principal Scientist at Simcyp

William Feehery, CEO of Certara, emphasized, "Certara is a science-driven organization, and our scientists are world leaders in their fields. Our clients rely on us to deliver advanced biosimulation software and the expert advice needed to interpret results for optimal strategic decision-making." His words reflect the confidence that clients place in Certara's capabilities.

Key Focus Areas in 2024 Publications

Certara's publications in 2024 portray its expansive role throughout the drug development continuum, from initial discovery phases to clinical products and post-approval processes. These contributions are categorized into two main themes that highlight emerging trends and best practices.

Innovations in Drug Development

The first theme focuses on the value and impact of biosimulation strategies:

• Pediatric oncology drug development and dosage optimization
• Mechanistic modeling’s influence on first-in-human dose predictions
• Utilization of exposure-response analyses for informed dosing
• Contribution of physiologically-based pharmacokinetics (PBPK) modeling to global health
• Understanding clinical trial variability through pharmacometrics
• Extended model-informed strategies that enhance drug development beyond trials

Best Practices for Drug Submission Processes

Furthermore, the second theme shines a light on recommended practices for integrating advanced technologies into drug approval processes, including:

• Emphasizing diversity in clinical trial enrollment to meet FDA standards
• Leveraging real-world data for managing clinical treatment guidelines
• Exploring synergies of generative AI in regulatory writing
• Understanding the essential role of submission leadership in process management

These publications reflect Certara's significant influence on modern medicinal development and the figures in research who lead the charge.

Learn More About Certara

Certara is dedicated to accelerating pharmaceutical advancements through innovative biosimulation software, services, and technology. The firm supports over 2,400 biopharmaceutical companies, academic institutions, and regulatory entities across 66 countries, making a substantial impact on global health.

Frequently Asked Questions

What is Certara known for?

Certara is recognized as a leader in model-informed drug development, utilizing advanced biosimulation to improve drug discovery and development processes.

How many publications did Certara have in 2024?

In 2024, Certara proudly achieved over 100 published papers across various scientific disciplines.

What is the significance of the Stanford/Elsevier list?

The Stanford/Elsevier list recognizes the top 2% of most-cited researchers globally, highlighting the exceptional contributions of scientists in their fields.

What role does Certara play in drug development?

Certara aids in drug development through its innovative biosimulation software and expert consultations, helping clients make informed decisions throughout the process.

How can I learn more about Certara's publications?

To explore more, you can visit Certara’s resource page dedicated to their publications.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.